{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:36:28Z","timestamp":1793813788315,"version":"4.6.1"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["ZIA SC 007263"],"award-info":[{"award-number":["ZIA SC 007263"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sacituzumab govitecan (SG) is an antibody drug conjugate targeting trophoblast cell surface antigen 2 (Trop2) that is approved for treatment of patients with metastatic triple negative breast cancer (TNBC). Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) agonists are antitumor agents that interact with death receptors on the cell surface to induce apoptosis in cancer cells, often sparing normal cells. In this study, we investigated whether combination treatment with SG and TRAIL agonists inhibit TNBC cell growth.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In vitro, 10 human TNBC cell lines and 4 non-modified, low passage patient derived TNBC cells were treated with SG and the TRAIL agonist Apo2L. Cell death was assessed via a propidium iodide-based assay while cell proliferation was measured using an ATP cell viability assay. The mode of cell death elicited by combination treatment was investigated by using inhibitors of apoptosis, necroptosis and ferroptosis. The drug effect on cell cycle was analyzed with flow cytometry. In vivo, NCr athymic nude (nu\/nu) female mice bearing HCC1806 TNBC xenografts were treated with SG and TRAIL agonists after which the effect of treatment on tumor growth and survival was evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>SG and TRAIL acted synergistically in all 10 TNBC cell lines as well as all 4 patient derived TNBC cells tested. Synergistic cell death and growth inhibition was observed in both Trop2 high-expressing and low-expressing cells, with data suggesting that the linker deconjugation and bystander effects of SG contribute to the efficacy in Trop2 low-expressing cells. Caspase-3\/7 assays as well as cell death assays using cell death inhibitors demonstrated that the lethality of dual treatment is primarily mediated by apoptosis. Additionally, SG alone and in combination with Apo2L induced cycle arrest at the G2\/M phase. Finally, xenograft models using HCC1806 bearing mice showed that dual treatment with SG and TRAIL agonists significantly inhibited tumor growth and caused a borderline significant benefit on survival with no toxicities noted for both drug treatments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Combination treatment with SG and TRAIL agonists induces synergistic lethality in TNBC cells in vitro and inhibits tumor growth in vivo, suggesting a potential clinical benefit of the combination therapy in TNBC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13058-026-02318-4","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T09:09:41Z","timestamp":1786698581000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Synergistic lethality of combination treatment with Trop2-directed antibody-drug conjugate sacituzumab govitecan and TRAIL agonists in triple negative breast cancer"],"prefix":"10.1186","volume":"28","author":[{"given":"Yonit A.","family":"Addissie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshimi E.","family":"Greer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayakumar","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley","family":"Lipkowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"issue":"4","key":"2318_CR1","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1038\/s41591-025-03502-3","volume":"31","author":"J Kim","year":"2025","unstructured":"Kim J, et al. Global patterns and trends in breast cancer incidence and mortality across 185 countries. Nat Med. 2025;31(4):1154\u201362.","journal-title":"Nat Med"},{"issue":"3","key":"2318_CR2","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.ccell.2019.02.001","volume":"35","author":"YZ Jiang","year":"2019","unstructured":"Jiang YZ, et al. Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies. Cancer Cell. 2019;35(3):428\u2013e4405.","journal-title":"Cancer Cell"},{"issue":"2","key":"2318_CR3","doi-asserted-by":"publisher","first-page":"241","DOI":"10.5858\/arpa.2013-0953-SA","volume":"138","author":"AC Wolff","year":"2014","unstructured":"Wolff AC, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med. 2014;138(2):241\u201356.","journal-title":"Arch Pathol Lab Med"},{"issue":"15 Pt 1","key":"2318_CR4","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","volume":"13","author":"R Dent","year":"2007","unstructured":"Dent R, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15 Pt 1):4429\u201334.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2318_CR5","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1200\/JCO.2007.14.4147","volume":"26","author":"C Liedtke","year":"2008","unstructured":"Liedtke C, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26(8):1275\u201381.","journal-title":"J Clin Oncol"},{"key":"2318_CR6","unstructured":"The Surveillance E. and End Results (SEER) Program Cancer Stat Facts: Female Breast Cancer Subtypes. 2022 [cited 2023 3\/29\/2023]; Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/breast-subtypes.html"},{"issue":"8","key":"2318_CR7","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1038\/sj.bjc.6604677","volume":"99","author":"D Fong","year":"2008","unstructured":"Fong D, et al. High expression of TROP2 correlates with poor prognosis in pancreatic cancer. Br J Cancer. 2008;99(8):1290\u20135.","journal-title":"Br J Cancer"},{"issue":"1","key":"2318_CR8","first-page":"73","volume":"9","author":"M Shen","year":"2021","unstructured":"Shen M, Liu S, Stoyanova T. The role of Trop2 in prostate cancer: an oncogene, biomarker, and therapeutic target. Am J Clin Exp Urol. 2021;9(1):73\u201387.","journal-title":"Am J Clin Exp Urol"},{"issue":"8","key":"2318_CR9","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1056\/NEJMoa1814213","volume":"380","author":"A Bardia","year":"2019","unstructured":"Bardia A, et al. Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer. N Engl J Med. 2019;380(8):741\u201351.","journal-title":"N Engl J Med"},{"issue":"7","key":"2318_CR10","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1369\/0022155411410430","volume":"59","author":"LP Stepan","year":"2011","unstructured":"Stepan LP, et al. Expression of Trop2 cell surface glycoprotein in normal and tumor tissues: potential implications as a cancer therapeutic target. J Histochem Cytochem. 2011;59(7):701\u201310.","journal-title":"J Histochem Cytochem"},{"issue":"10","key":"2318_CR11","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1007\/s40265-020-01337-5","volume":"80","author":"YY Syed","year":"2020","unstructured":"Syed YY. Sacituzumab Govitecan: First Approval. Drugs. 2020;80(10):1019\u201325.","journal-title":"Drugs"},{"issue":"26","key":"2318_CR12","doi-asserted-by":"publisher","first-page":"22496","DOI":"10.18632\/oncotarget.4318","volume":"6","author":"DM Goldenberg","year":"2015","unstructured":"Goldenberg DM, et al. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC). Oncotarget. 2015;6(26):22496\u2013512.","journal-title":"Oncotarget"},{"key":"2318_CR13","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.2147\/OTT.S162447","volume":"12","author":"S Zaman","year":"2019","unstructured":"Zaman S, et al. Targeting Trop-2 in solid tumors: future prospects. Onco Targets Ther. 2019;12:1781\u201390.","journal-title":"Onco Targets Ther"},{"issue":"22","key":"2318_CR14","doi-asserted-by":"publisher","first-page":"5131","DOI":"10.1158\/1078-0432.CCR-15-0670","volume":"21","author":"RM Sharkey","year":"2015","unstructured":"Sharkey RM, et al. Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2-SN-38 Antibody Conjugate (Sacituzumab Govitecan). Clin Cancer Res. 2015;21(22):5131\u20138.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2318_CR15","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13045-021-01035-z","volume":"14","author":"C Criscitiello","year":"2021","unstructured":"Criscitiello C, Morganti S, Curigliano G. Antibody-drug conjugates in solid tumors: a look into novel targets. J Hematol Oncol. 2021;14(1):20.","journal-title":"J Hematol Oncol"},{"issue":"6","key":"2318_CR16","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1080\/19420862.2019.1632115","volume":"11","author":"DM Goldenberg","year":"2019","unstructured":"Goldenberg DM, Sharkey RM. Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecan. MAbs. 2019;11(6):987\u201395.","journal-title":"MAbs"},{"issue":"5","key":"2318_CR17","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1021\/acs.bioconjchem.5b00223","volume":"26","author":"TM Cardillo","year":"2015","unstructured":"Cardillo TM, et al. Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2\/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers. Bioconjug Chem. 2015;26(5):919\u201331.","journal-title":"Bioconjug Chem"},{"key":"2318_CR18","doi-asserted-by":"publisher","first-page":"118","DOI":"10.3389\/fonc.2020.00118","volume":"10","author":"E Perrone","year":"2020","unstructured":"Perrone E, et al. Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer. Front Oncol. 2020;10:118.","journal-title":"Front Oncol"},{"issue":"10","key":"2318_CR19","doi-asserted-by":"publisher","first-page":"3157","DOI":"10.1158\/1078-0432.CCR-10-2939","volume":"17","author":"TM Cardillo","year":"2011","unstructured":"Cardillo TM, et al. Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys. Clin Cancer Res. 2011;17(10):3157\u201369.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2318_CR20","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.annonc.2021.06.002","volume":"32","author":"A Bardia","year":"2021","unstructured":"Bardia A, et al. Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. Ann Oncol. 2021;32(9):1148\u201356.","journal-title":"Ann Oncol"},{"issue":"16","key":"2318_CR21","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","volume":"384","author":"A Bardia","year":"2021","unstructured":"Bardia A, et al. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. N Engl J Med. 2021;384(16):1529\u201341.","journal-title":"N Engl J Med"},{"issue":"13","key":"2318_CR22","doi-asserted-by":"publisher","first-page":"3405","DOI":"10.1158\/1078-0432.CCR-16-2401","volume":"23","author":"TM Cardillo","year":"2017","unstructured":"Cardillo TM, et al. Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132, Plus PARP Inhibitors in BRCA1\/2-wild-type Triple-Negative Breast Cancer. Clin Cancer Res. 2017;23(13):3405\u201315.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2318_CR23","doi-asserted-by":"publisher","first-page":"111283","DOI":"10.1016\/j.isci.2024.111283","volume":"27","author":"JR Nair","year":"2024","unstructured":"Nair JR, et al. Distinct effects of sacituzumab govitecan and berzosertib on DNA damage response in ovarian cancer. iScience. 2024;27(12):111283.","journal-title":"iScience"},{"issue":"1","key":"2318_CR24","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/sj.cdd.4401187","volume":"10","author":"HN LeBlanc","year":"2003","unstructured":"LeBlanc HN, Ashkenazi A. Apo2L\/TRAIL and its death and decoy receptors. Cell Death Differ. 2003;10(1):66\u201375.","journal-title":"Cell Death Differ"},{"issue":"2","key":"2318_CR25","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s10549-015-3673-z","volume":"155","author":"JL Dine","year":"2016","unstructured":"Dine JL, et al. The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl. Breast Cancer Res Treat. 2016;155(2):235\u201351.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"2318_CR26","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13058-019-1116-1","volume":"21","author":"YE Greer","year":"2019","unstructured":"Greer YE, et al. MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 agonist, causes regression of orthotopic tumors and inhibits outgrowth of metastatic triple-negative breast cancer. Breast Cancer Res. 2019;21(1):27.","journal-title":"Breast Cancer Res"},{"issue":"2","key":"2318_CR27","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s10549-008-9924-5","volume":"113","author":"M Rahman","year":"2009","unstructured":"Rahman M, et al. TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype. Breast Cancer Res Treat. 2009;113(2):217\u201330.","journal-title":"Breast Cancer Res Treat"},{"issue":"12","key":"2318_CR28","first-page":"4892","volume":"61","author":"M Cuello","year":"2001","unstructured":"Cuello M, et al. Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res. 2001;61(12):4892\u2013900.","journal-title":"Cancer Res"},{"issue":"3","key":"2318_CR29","first-page":"734","volume":"59","author":"MM Keane","year":"1999","unstructured":"Keane MM, et al. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res. 1999;59(3):734\u201341.","journal-title":"Cancer Res"},{"issue":"10 Pt 1","key":"2318_CR30","first-page":"3731","volume":"9","author":"DJ Buchsbaum","year":"2003","unstructured":"Buchsbaum DJ, et al. Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and\/or radiation therapy in a human breast cancer model. Clin Cancer Res. 2003;9(10 Pt 1):3731\u201341.","journal-title":"Clin Cancer Res"},{"issue":"17","key":"2318_CR31","first-page":"5390","volume":"63","author":"TR Singh","year":"2003","unstructured":"Singh TR, et al. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand\/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo. Cancer Res. 2003;63(17):5390\u2013400.","journal-title":"Cancer Res"},{"issue":"4","key":"2318_CR32","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1073\/pnas.030545097","volume":"97","author":"AM Chinnaiyan","year":"2000","unstructured":"Chinnaiyan AM, et al. Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc Natl Acad Sci U S A. 2000;97(4):1754\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"20","key":"2318_CR33","first-page":"5800","volume":"62","author":"T Naka","year":"2002","unstructured":"Naka T, et al. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients\u2019 colon tumors grown in SCID mice. Cancer Res. 2002;62(20):5800\u20136.","journal-title":"Cancer Res"},{"issue":"1","key":"2318_CR34","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1479-5876-3-22","volume":"3","author":"BL Hylander","year":"2005","unstructured":"Hylander BL, et al. The anti-tumor effect of Apo2L\/TRAIL on patient pancreatic adenocarcinomas grown as xenografts in SCID mice. J Transl Med. 2005;3(1):22.","journal-title":"J Transl Med"},{"key":"2318_CR35","unstructured":"NCI Patient-Derived Models Repository (PDMR). 2025 https:\/\/pdmr.cancer.gov\/models\/database.htm"},{"key":"2318_CR36","doi-asserted-by":"crossref","unstructured":"Wisniewski DJ et al. EGFR amplification and PI3K pathway mutations identify a subset of breast cancers that synergistically respond to EGFR and PI3K inhibition. bioRxiv, 2025.","DOI":"10.1101\/2025.06.03.657674"},{"key":"2318_CR37","unstructured":"SynergyFinder. SynergyFinder\u2009+\u2009a FAIR tool for analyzing drug combination discovery August 2022 to November 2025 https:\/\/synergyfinder.org"},{"issue":"2","key":"2318_CR38","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s10549-009-0571-2","volume":"122","author":"LM Murrow","year":"2010","unstructured":"Murrow LM, et al. Identification of WEE1 as a potential molecular target in cancer cells by RNAi screening of the human tyrosine kinome. Breast Cancer Res Treat. 2010;122(2):347\u201357.","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"2318_CR39","doi-asserted-by":"publisher","first-page":"e0216967","DOI":"10.1371\/journal.pone.0216967","volume":"14","author":"MS Liyasova","year":"2019","unstructured":"Liyasova MS, et al. Cbl interacts with multiple E2s in vitro and in cells. PLoS ONE. 2019;14(5):e0216967.","journal-title":"PLoS ONE"},{"issue":"1","key":"2318_CR40","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0022-3565(24)29298-3","volume":"299","author":"SK Kelley","year":"2001","unstructured":"Kelley SK, et al. Preclinical studies to predict the disposition of Apo2L\/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther. 2001;299(1):31\u20138.","journal-title":"J Pharmacol Exp Ther"},{"issue":"10","key":"2318_CR41","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1593\/neo.12956","volume":"14","author":"LD Volk-Draper","year":"2012","unstructured":"Volk-Draper LD, et al. Novel model for basaloid triple-negative breast cancer: behavior in vivo and response to therapy. Neoplasia. 2012;14(10):926\u201342.","journal-title":"Neoplasia"},{"issue":"1","key":"2318_CR42","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1128\/MCB.20.1.205-212.2000","volume":"20","author":"SB Gibson","year":"2000","unstructured":"Gibson SB, et al. Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL. Mol Cell Biol. 2000;20(1):205\u201312.","journal-title":"Mol Cell Biol"},{"issue":"4","key":"2318_CR43","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1002\/ijc.10948","volume":"104","author":"XX Wu","year":"2003","unstructured":"Wu XX, et al. Enhancement of TRAIL\/Apo2L-mediated apoptosis by adriamycin through inducing DR4 and DR5 in renal cell carcinoma cells. Int J Cancer. 2003;104(4):409\u201317.","journal-title":"Int J Cancer"},{"key":"2318_CR44","unstructured":"Administration, U.S.F.a.D. FDA approves sacituzumab govitecan-hziy for HR-positive breast cancer. 2023 [cited 2026 May 2]; Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-sacituzumab-govitecan-hziy-hr-positive-breast-cancer"},{"issue":"9","key":"2318_CR45","first-page":"3535","volume":"61","author":"JC Cusack Jr","year":"2001","unstructured":"Cusack JC Jr., et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res. 2001;61(9):3535\u201340.","journal-title":"Cancer Res"},{"issue":"1","key":"2318_CR46","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.canlet.2008.08.037","volume":"274","author":"Y Liu","year":"2009","unstructured":"Liu Y, et al. Inhibition of Akt signaling by SN-38 induces apoptosis in cervical cancer. Cancer Lett. 2009;274(1):47\u201353.","journal-title":"Cancer Lett"},{"issue":"2","key":"2318_CR47","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/sj.bjc.6604082","volume":"98","author":"P Lagadec","year":"2008","unstructured":"Lagadec P, et al. Pharmacological targeting of NF-kappaB potentiates the effect of the topoisomerase inhibitor CPT-11 on colon cancer cells. Br J Cancer. 2008;98(2):335\u201344.","journal-title":"Br J Cancer"},{"issue":"3","key":"2318_CR48","first-page":"665","volume":"5","author":"CM Whitacre","year":"1999","unstructured":"Whitacre CM, et al. Detection of poly(ADP-ribose) polymerase cleavage in response to treatment with topoisomerase I inhibitors: a potential surrogate end point to assess treatment effectiveness. Clin Cancer Res. 1999;5(3):665\u201372.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"2318_CR49","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1517\/14728222.2010.519701","volume":"14","author":"J Abdulghani","year":"2010","unstructured":"Abdulghani J, El-Deiry WS. TRAIL receptor signaling and therapeutics. Expert Opin Ther Targets. 2010;14(10):1091\u2013108.","journal-title":"Expert Opin Ther Targets"},{"issue":"4","key":"2318_CR50","first-page":"1667","volume":"53","author":"Y Wang","year":"2018","unstructured":"Wang Y, et al. Radiosensitization by irinotecan is attributed to G2\/M phase arrest, followed by enhanced apoptosis, probably through the ATM\/Chk\/Cdc25C\/Cdc2 pathway in p53-mutant colorectal cancer cells. Int J Oncol. 2018;53(4):1667\u201380.","journal-title":"Int J Oncol"},{"issue":"4","key":"2318_CR51","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/S0302-2838(02)00321-4","volume":"42","author":"M Ueno","year":"2002","unstructured":"Ueno M, et al. SN-38 induces cell cycle arrest and apoptosis in human testicular cancer. Eur Urol. 2002;42(4):390\u20137.","journal-title":"Eur Urol"},{"issue":"43","key":"2318_CR52","doi-asserted-by":"publisher","first-page":"3849","DOI":"10.18632\/oncotarget.27766","volume":"11","author":"TM Cardillo","year":"2020","unstructured":"Cardillo TM, et al. Predictive biomarkers for sacituzumab govitecan efficacy in Trop-2-expressing triple-negative breast cancer. Oncotarget. 2020;11(43):3849\u201362.","journal-title":"Oncotarget"},{"issue":"12","key":"2318_CR53","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1158\/1078-0432.CCR-16-2273","volume":"23","author":"H Kim","year":"2017","unstructured":"Kim H, et al. Targeting the ATR\/CHK1 Axis with PARP Inhibition Results in Tumor Regression in BRCA-Mutant Ovarian Cancer Models. Clin Cancer Res. 2017;23(12):3097\u2013108.","journal-title":"Clin Cancer Res"},{"issue":"19","key":"2318_CR54","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1200\/JCO.2016.70.8297","volume":"35","author":"A Bardia","year":"2017","unstructured":"Bardia A, et al. Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer. J Clin Oncol. 2017;35(19):2141\u20138.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2318_CR55","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1158\/1535-7163.MCT-22-0375","volume":"22","author":"A Kopp","year":"2023","unstructured":"Kopp A, et al. Antibody-Drug Conjugate Sacituzumab Govitecan Drives Efficient Tissue Penetration and Rapid Intracellular Drug Release. Mol Cancer Ther. 2023;22(1):102\u201311.","journal-title":"Mol Cancer Ther"},{"issue":"12","key":"2318_CR56","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1038\/bjc.2017.367","volume":"117","author":"AH Staudacher","year":"2017","unstructured":"Staudacher AH, Brown MP. Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required? Br J Cancer. 2017;117(12):1736\u201342.","journal-title":"Br J Cancer"},{"issue":"8","key":"2318_CR57","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1158\/1078-0432.CCR-24-1525","volume":"31","author":"SM Tolaney","year":"2025","unstructured":"Tolaney SM, et al. The Mode of Action and Clinical Outcomes of Sacituzumab Govitecan in Solid Tumors. Clin Cancer Res. 2025;31(8):1390\u20139.","journal-title":"Clin Cancer Res"},{"issue":"14","key":"2318_CR58","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.21037\/atm-21-1103","volume":"9","author":"DV Santi","year":"2021","unstructured":"Santi DV, Cabel L, Bidard FC. Does sacituzumab-govitecan act as a conventional antibody drug conjugate (ADC), a prodrug of SN-38 or both? Ann Transl Med. 2021;9(14):1113.","journal-title":"Ann Transl Med"},{"key":"2318_CR59","doi-asserted-by":"publisher","first-page":"1679648","DOI":"10.3389\/fimmu.2025.1679648","volume":"16","author":"J Piekarz","year":"2025","unstructured":"Piekarz J, et al. Sacituzumab govitecan as a therapeutic breakthrough in the treatment of triple-negative breast cancer: a systematic review of clinical trials. Front Immunol. 2025;16:1679648.","journal-title":"Front Immunol"},{"issue":"1","key":"2318_CR60","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1042\/BST20220098","volume":"51","author":"F Di Cristofano","year":"2023","unstructured":"Di Cristofano F, et al. Therapeutic targeting of TRAIL death receptors. Biochem Soc Trans. 2023;51(1):57\u201370.","journal-title":"Biochem Soc Trans"},{"issue":"1","key":"2318_CR61","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/1535-7163.MCT-11-0434","volume":"11","author":"CT Hellwig","year":"2012","unstructured":"Hellwig CT, Rehm M. TRAIL signaling and synergy mechanisms used in TRAIL-based combination therapies. Mol Cancer Ther. 2012;11(1):3\u201313.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"2318_CR62","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1158\/1541-7786.MCR-11-0500","volume":"10","author":"SV Garimella","year":"2012","unstructured":"Garimella SV, Rocca A, Lipkowitz S. WEE1 inhibition sensitizes basal breast cancer cells to TRAIL-induced apoptosis. Mol Cancer Res. 2012;10(1):75\u201385.","journal-title":"Mol Cancer Res"},{"key":"2318_CR63","doi-asserted-by":"crossref","unstructured":"Kundu M et al. TRAIL-induced cytokine production via NFKB2 pathway promotes neutrophil chemotaxis and immune suppression in triple negative breast cancers. bioRxiv, 2024.","DOI":"10.1101\/2024.07.19.604341"},{"key":"2318_CR64","doi-asserted-by":"publisher","first-page":"217692","DOI":"10.1016\/j.canlet.2025.217692","volume":"620","author":"M Kundu","year":"2025","unstructured":"Kundu M, et al. TRAIL induces cytokine production via the NFkB2 pathway promoting neutrophil chemotaxis and neutrophil-mediated immune-suppression in triple negative breast cancer cells. Cancer Lett. 2025;620:217692.","journal-title":"Cancer Lett"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02318-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-026-02318-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02318-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T10:04:59Z","timestamp":1786701899000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13058-026-02318-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2318"],"URL":"https:\/\/doi.org\/10.1186\/s13058-026-02318-4","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,14]]},"assertion":[{"value":"23 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animal experiments were performed under approved NCI Animal Use agreements.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"144"}}